OptimizeRx (OPRX) director awarded 17,258 restricted stock units in Form 4 filing

Rhea-AI Filing Summary

Presti Mariyamma Varghese reported acquisition or exercise transactions in this Form 4 filing.

OptimizeRx Corp director Presti Mariyamma Varghese received a grant of 17,258 restricted stock units (RSUs) of common stock. The award was made at no cash cost per unit and increases her direct holdings to 30,318 shares after the transaction. The RSUs represent a contingent right to receive shares that will vest in full on the earlier of the first anniversary of the grant date or the date of OptimizeRx’s next annual meeting of shareholders.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Presti Mariyamma Varghese

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	17,258	$0.00	--

Holdings After Transaction: Common Stock — 30,318 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSUs granted: 17,258 shares Transaction price per share: $0.0000 Shares owned after transaction: 30,318 shares +1 more

4 metrics

RSUs granted 17,258 shares Restricted stock units of common stock granted to director

Transaction price per share $0.0000 Award granted as stock-based compensation, no cash paid

Shares owned after transaction 30,318 shares Direct holdings following the RSU grant

Vesting period 1 year maximum Vests on earlier of first anniversary or next annual meeting

Key Terms

restricted stock units, contingent right, annual meeting of shareholders

3 terms

restricted stock units financial

"Grant of restricted stock units representing a contingent right to receive shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"representing a contingent right to receive shares of OptimizeRx common stock"

annual meeting of shareholders financial

"the date of the Company's next annual meeting of shareholders"

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Presti Mariyamma Varghese

(Last) (First) (Middle)

C/O OPTIMIZERX CORPORATION

260 CHARLES STREET, SUITE 302

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
OptimizeRx Corp [ OPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/09/2026		A		17,258(1)	A	$0	30,318	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Grant of restricted stock units representing a contingent right to receive shares of OptimizeRx common stock. The restricted stock units will vest in full on the earlier of the first anniversary of the date of the grant or the date of the Company's next annual meeting of shareholders.

Remarks:

The filing of this Statement shall not be construed as an admission (a) that the person filing this Statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this Statement, or (b) that this Statement is legally required to be filed by such person.

	/s/ Marion Odence-Ford, by Power of Attorney	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did OptimizeRx (OPRX) report for Presti Mariyamma Varghese?

OptimizeRx reported a stock-based compensation grant to director Presti Mariyamma Varghese. She received 17,258 restricted stock units of common stock, awarded at no cash cost, increasing her direct holdings to 30,318 shares after the transaction as disclosed in the Form 4 filing.

How many OptimizeRx (OPRX) shares were granted in the latest Form 4 filing?

The filing shows a grant of 17,258 restricted stock units. These RSUs represent a contingent right to receive shares of OptimizeRx common stock and will vest in full on the earlier of the first anniversary of the grant date or the company’s next annual shareholder meeting.

What is the vesting schedule for the OptimizeRx (OPRX) RSUs granted to Presti Mariyamma Varghese?

The RSUs vest in a single tranche based on time or the next meeting. They will fully vest on the earlier of the first anniversary of the grant date or the date of OptimizeRx’s next annual meeting of shareholders, subject to the award’s standard conditions.

Did Presti Mariyamma Varghese pay anything for the OptimizeRx (OPRX) RSU grant?

No cash was paid for the RSU grant. The Form 4 reports a transaction price per share of 0.0000, indicating this is a stock-based compensation award rather than an open-market purchase, consistent with typical director equity compensation practices.

What are Presti Mariyamma Varghese’s OptimizeRx (OPRX) holdings after the RSU award?

After the reported grant, her direct OptimizeRx holdings total 30,318 shares. This figure reflects the shares beneficially owned following the transaction, as disclosed in the Form 4, and includes the effect of the 17,258-share restricted stock unit award.